The study authors reinforced the idea that NNMT inhibition could potentially treat obesity and related metabolic comorbidities [6]
When administering AOD 9604 in research settings, subcutaneous injection is the preferred method for studying its effects on fat mass, fat breakdown, and fat oxidation
This guide covers everything researchers need to know
Critics, including the FDA's own scientific staff, argue that insufficient evidence exists to ensure these compounds are safe for human use
It is not a substitute for medical judgment, product labeling, or institutional protocols
In late July 2026 an FDA advisory committee then recommended six peptides including BPC-157, TB-500, KPV, and MOTS-c for the compounding list